Insider Trading May 11, 2026 05:58 PM

Aflac Director Joseph L. Moskowitz Executes Stock Sale Under Rule 10b5-1 Plan

The transaction involves a disposal of 600 shares amid mixed first-quarter earnings results for the insurance provider.

By Derek Hwang AFL

A recent Form 4 filing has revealed that Joseph L. Moskowitz, a director at Aflac Inc. (NYSE: AFL), has completed a sale of company common stock. The transaction occurred on May 8, 2026, during which Mr. Moskowitz disposed of 600 shares. These shares were sold at a price point of $113.73 per share, resulting in total proceeds of $68,238. Following this specific liquidation, Mr. Moskowitz maintains a direct ownership stake of 25,368 shares in the corporation.This sale was not an impromptu market move but was conducted through a Rule 10b5-1 trading plan, which had been established by Mr. Moskowitz on December 4, 2025. This type of planned trading is often used to manage transactions in advance of potential non-public information.

Aflac Director Joseph L. Moskowitz Executes Stock Sale Under Rule 10b5-1 Plan
AFL

Key Points

  • Director Joseph L. Moskowitz sold 600 shares at $113.73 per share under a 10b5-1 plan.
  • Aflac reported Q1 2026 revenue of $4.35 billion, exceeding the $4.18 billion forecast, but EPS of $1.75 missed the $1.80 estimate.
  • The company is expanding its administrative operations with a new office in South Portland to manage Maine's Paid Family and Medical Leave program.

Aflac Inc. (NYSE: AFL) director Joseph L. Moskowitz has completed a sale of the company's common stock, according to documentation found in a recent Form 4 filing. On May 8, 2026, Mr. Moskowitz disposed of 600 shares at an individual price of $113.73 per share. The total value realized from this transaction was $68,238. After the completion of this sale, Mr. Moskowitz’s direct holdings in Aflac common stock stand at 25,368 shares.

The disposal was carried out pursuant to a Rule 10b5-1 trading plan that Mr. Moskowitz had adopted previously on December 4, 2025. This planned transaction comes at a time when Aflac's stock is trading at $115.48, a level situated near its 52-week high of $119.32.

From a valuation perspective, analysis indicates the stock appears undervalued with a P/E ratio of 13.04. Aflac has demonstrated long-term commitment to its shareholders through dividend growth, having raised its dividend for 42 consecutive years. The current yield for investors stands at 2.11%.

The insider activity follows a period of mixed financial results reported by Aflac Incorporated during the first quarter of 2026. The company's revenue reached $4.35 billion, which exceeded the anticipated forecast of $4.18 billion. However, despite the strong sales performance, the earnings per share (EPS) recorded at $1.75, falling short of the expected $1.80 mark. These varying metrics have led to differing sentiments within the market regarding the company's immediate trajectory.

In recent corporate governance developments, Aflac shareholders participated in an annual meeting where they approved nearly all pending proposals. The only measure not passed was a proposal seeking an independent board chairman. During this meeting, 11 directors were elected to the board, and KPMG LLP was ratified as the firm's independent registered public accounting firm.

Beyond financial reporting and governance, Aflac has expanded its operational footprint by opening a new office in South Portland. This location is tasked with managing Maine’s Paid Family and Medical Leave program. The office will oversee the administration of claims for more than 500,000 eligible workers as the state begins issuing benefits.


Key Insights

  • Insider Trading Activity: The sale by Director Joseph L. Moskowitz was executed via a pre-arranged Rule 10b5-1 plan established in late 2025, providing context for the timing of the disposal.
  • Financial Divergence: Aflac is experiencing a divergence between top-line growth and bottom-line expectations, with revenue beating forecasts while EPS trailed anticipated targets.
  • Operational Expansion: The company is increasing its administrative capacity through new regional infrastructure, specifically targeting state-managed benefit programs in Maine.

These developments impact the insurance and financial services sectors by highlighting how large-scale providers manage regulatory expansions and shifting profitability margins.


Risks and Uncertainties

  • Earnings Volatility: The discrepancy between revenue beats and EPS misses suggests potential uncertainty regarding expense management or profit margins, which can affect investor confidence in the financial sector.
  • Governance Shifts: While most proposals passed, the rejection of a measure for an independent board chairman may be a point of observation for those monitoring corporate governance trends within large-cap insurance firms.

Risks

  • Missed earnings per share expectations could impact stock sentiment in the insurance sector.
  • The rejection of an independent board chairman proposal reflects ongoing governance considerations at the company level.

More from Insider Trading

Edwards Lifesciences CEO Executes Multi-Million Dollar Share Sale via Pre-Set Trading Plan May 12, 2026 Covista CFO Executes $1.26 Million Stock Sale via Pre-Scheduled Trading Plan May 12, 2026 Covista Executive Executes Planned Share Sale Amidst Corporate Growth and Financial Restructuring May 12, 2026 Covista Executive Executes $1.22 Million Stock Sale Under Pre-Planned Trading Program May 12, 2026 Ameriprise Financial Director Executes Stock Sale Amid Strong Earnings Performance May 12, 2026